Ecological risk assessment of 50 emerging contaminants in surface water of the Greater Bay Area, China.

Sci Total Environ

State Key Laboratory of Environmental Criteria and Risk Assessment, Chinese Research Academy of Environmental Sciences, Beijing 100012, China. Electronic address:

Published: January 2024

Ecological risk assessment of emerging contaminants (ECs) is an international research hotspot and is also the focus of China's "14th Five-Year Plan". The Greater Bay Area (GBA) is one of the four major bay areas in the world and the most dynamic region in China. However, there are few studies on the risk assessment of ECs in the GBA, and there needs to be a systematic and comprehensive assessment of the ecological risk of ECs. We selectively collected environmental concentration and toxicity data reported in the literature before 2022 for 50 representative ECs. We use risk quotient (RQ), semi-probability, Margin of Safety (MOS), and joint Probability curve (JPC) methods for multiple-level risk assessment. The RQ results showed that there were primary ecological risks in 20 ECs. Nine ECs were screened by the semi-probability, MOS, and JPC methods. The total risk probability of nonylphenol (NP) to the GBA was 12.11 %, and the risk to the aquatic ecological environment was the highest, followed by α-endosulfan (α-END) and erythromycin (ERY). At the same time, a comprehensive assessment method was adopted to screen the list of medium and high-risk priority pollutants in the GBA. According to the comprehensive evaluation results, although the risk is low, perfluorooctanoic acid (PFOA) still deserves widespread attention. The results showed that NP, α-END, ERY, and PFOA may be the most concerned ECs in the GBA. This research fills the gap on the ECs ecological risk assessment of the GBA and can provide a theoretical reference for managers in the follow-up of ECs regulatory governance.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.scitotenv.2023.168105DOI Listing

Publication Analysis

Top Keywords

risk assessment
20
ecological risk
16
risk
9
ecs
9
assessment emerging
8
emerging contaminants
8
greater bay
8
bay area
8
ecs gba
8
comprehensive assessment
8

Similar Publications

Background: Availability of amyloid modifying therapies will dramatically increase the need for disclosure of Alzheimer's disease (AD) related genetic and/or biomarker test results. The 21st Century Cares Act requires the immediate return of most medical test results, including AD biomarkers. A shortage of genetic counselors and dementia specialists already exists, thus driving the need for scalable methods to responsibly communicate test results.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Karolinska Institute, Stockholm, Södermanland and Uppland, Sweden.

Background: Novel anti-amyloid therapies (AAT) for Alzheimer's Disease (AD) have recently been approved in the United States, Japan and China, and are under regulatory review in Europe. Questions remain regarding the long-term effectiveness and value of these drugs when used in routine clinical practice. Data from follow-up studies will be important to inform their optimal use, including criteria for treatment initiation, monitoring strategies, stopping rules, pricing and reimbursement considerations.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Signant Health, Blue Bell, PA, USA.

Background: Rater change is inevitable in often lengthy clinical trials in Alzheimer's disease. Other groups have previously assessed the impact of rater change on data variability. Their conclusions varied, possibly due to differing methodologies (e.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Unlearn.AI, San Francisco, CA, USA.

Background: Pivotal Alzheimer's Disease (AD) trials typically require thousands of participants, resulting in long enrollment timelines and substantial costs. We leverage deep learning predictive models to create prognostic scores (forecasted control outcome) of trial participants and in combination with a linear statistical model to increase statistical power in randomized clinical trials (RCT). This is a straightforward extension of the traditional RCT analysis, allowing for ease of use in any clinical program.

View Article and Find Full Text PDF

Background: Hypertension is a risk factor for cognitive impairment and dementia. Anti-hypertensives (AHT) are commonly used in old age, but their association with cognition and brain pathology is not well understood.

Method: To investigate the relation of AHT with change in cognitive function and postmortem brain pathology, we evaluated 4,207 older persons without known dementia at enrollment and a subset of 1880 participants who died and came to autopsy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!